|
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Seagen; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda |
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen Oncology; Pharmacyclics; Sanofi; Seagen |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Takeda |
Speakers' Bureau - Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen |
|
|
|
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Oncopeptides; Takeda (Inst) |
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Genmab; Janssen; Takeda |
Research Funding - Janssen |
|
|
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene |
Research Funding - Janssen medical Affairs (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen Oncology; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Janssen; Sanofi; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Sanofi; Takeda |
|
|
Honoraria - Amgen; Celgene; Johnson & Johnson; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Sanofi; Takeda |
Research Funding - Amgen; Celgene; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Pierre Fabre; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Roche; Takeda |
Travel, Accommodations, Expenses - Takeda |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
Honoraria - Abbvie; Amgen; Celgene; Janssen-Cilag; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen-Cilag |